a cutoff of 0.05 was used when generating this data, but note that all FDR values are far below this
Stacking with other experimental peptides (like AOD-9604) is speculative and not clinically tested
It is common in clinical practice to draw a high-viscosity solution with a lower-gauge needle (e.g., 18G - 20G) and then switch to a higher-gauge needle (e.g., 23G - 25G) for the administration
In some embodiments, the otic pharmaceutical formulation comprises about 65% by weight of the triglycerides
In skeletal muscle, it inhibits muscle atrophy, preserves muscle strength, and enhances exercise endurance, as well as increases glucose uptake and storage in myocytes [41]
Yes, but clearly specify which formulation the patient receives and note regulatory or sourcing differences